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Multi-armAbstract Background: The past three decades have seen rapid improvements in the diagnosis
and treatment of most cancers and the most important contributor has been research.
Progress in rare cancers has been slower, not least because of the challenges of undertaking
research.
Settings: The International Rare Cancers Initiative (IRCI) is a partnership which aims to
stimulate and facilitate the development of international clinical trials for patients with rare
cancers. It is focused on interventional – usually randomised – clinical trials with the clear goal
of improving outcomes for patients. The key challenges are organisational and methodolog-
ical. A multi-disciplinary workshop to review the methods used in ICRI portfolio trials was
held in Amsterdam in September 2013. Other as-yet unrealised methods were also discussed.
Results: The IRCI trials are each presented to exemplify possible approaches to designing
credible trials in rare cancers. Researchers may consider these for use in future trials and
understand the choices made for each design.
Interpretation: Trials can be designed using a wide array of possibilities. There is no ‘one size
fits all’ solution. In order to make progress in the rare diseases, decisions to change practice
will have to be based on less direct evidence from clinical trials than in more common diseases.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/3.0/).1. Introduction
The past three decades have seen rapid improvements
in the diagnosis and treatment of cancer, and conse-
quently in survival and other outcomes for cancer
patients. Many factors have contributed to this pro-
gress, including public education and screening for ear-
lier diagnosis, better access to diagnostic and treatment
services, improved training and quality control in treat-
ment delivery and improved supportive care.
The most important contributor to progress has been
research, with public and private sector investment in
preclinical and clinical research leading to rapid expan-
sion of the evidence-base. For example, the introduction
of a United Kingdom (UK) government-supported
National Cancer Research Network from 2001 led to
>5-fold increase in the number of cancer patients partic-
ipating in research, so that 20% of all cancer patients
participate in a national portfolio of studies.
Research activity has unsurprisingly focused on com-
mon cancers: industry prioritises cancers with the largest
potential market and public sector funders prioritise
those with the greatest clinical need. Furthermore,
organising and delivering adequately-powered studiesrequires sufficient patients and a credible trial within a
reasonable timescale can be infeasible in a rare cancer
in a single country. Consequently, treatment is often
based on insufficient evidence, and access to innovative
drugs and technologies for research is poor.
This presents a major public health challenge. Rare
cancers (incidence <6/100,000/year) [1] are a paradoxi-
cally common problem, accounting for 22% of all cancer
diagnoses, higher than any single common cancer. But
median survival for patients with rare cancer is typically
poor and, unlike most common cancers, it is not
improving.
The International Rare Cancers Initiative – IRCI –
was formed in 2011 as a partnership between the
National Institute of Health Research Cancer Research
Network (NCRN) in England, Cancer Research UK,
the Europe an Organisation for Research and Treat-
ment of Cancer (EORTC) and the United States of
America (USA) National Cancer Institute Cancer Ther-
apy Evaluation Program (CTEP), and was joined in
2013 by the French National Institute of Cancer (INCa).
IRCI’s aim is to stimulate and facilitate the development
of international clinical trials for patients with rare
cancers. It is focused on interventional – usually
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improving outcomes for patients.
IRCI faces two important challenges. The first is
organisational: bringing together researchers from many
countries, achieving consensus and overcoming the
many regulatory and financial barriers which can
impede the smooth running of international clinical
research. The second is methodological: even with inter-
national collaboration, standard trial designs may
require unfeasibly large recruitment targets for the set-
ting, which calls for innovative methodologies to
research.
A multi-disciplinary workshop to review the methods
used in ICRI portfolio trials was held in Amsterdam in
September 2013. Other as-yet unrealised methods were
also discussed. Here, we present some of the methods
available and illustrate them with examples from the
IRCI portfolio. The aim is that researchers may consider
these for use in future trials and understand the choices
made for each design.
2. Methods, findings
The IRCI trials are each presented to exemplify one
possible approach to the challenges of designing credible
trials in rare cancers. Several trials used multiple
such approaches, as will be clear from the description
(Tables 1 and 2)3.
2.1. Utilise a phase II design (Anal cancer)
One choice in the absence of sufficient patients for a
phase III trial is to use a randomised phase II design
to develop a collaboration for the future, as in InterA-
ACT, an international, multicentre, open-label, ran-
domised controlled trial (RCT). It is the first
prospective trial of first-line treatment for patients with
inoperable locally-recurrent or metastatic squamous cell
carcinoma of the anus (SCCA). Eighty patients will be
randomised to either cisplatin 5-FU or
carboplatin + paclitaxel.3 Associations: InterAACT/IRCI 003; Sheela Rao (Chief Investiga-
tor), Clare Peckitt (Trial Statistician), Francesco Sclafani, Al Benson,
Dirk Arnold, Cathy Eng, Rob Glynne-Jones. ADT in advanced SGCs/
IRCI 007; Lisa Licitra (Chief Investigator), Catherine Fortpied (Trial
Statistician), Alan Ho, Kevin Harrington.GOG-0277/IRCI 001; Mar-
tee Hensley (Chief Investigator), Virginia Filiaci (Trial Statistician),
Helen Hatcher, Jean-Yves Blay. MEKi +/- AKTi in UM/IRCI 005;
Richard Carvajal (Chief Investigator); Kathy Panageas (Trial Statis-
tician), Ernie Marshall, Poulam M. Patel, Serge Leyvraz. HGUS/IRCI
006; Isabelle Ray-Coquard (Chief Investigator), Corneel Coens (Trial
Statistician), Helena Earl. BALLAD/IRCI 002; Richard Wilson (Chief
Investigator), James Paul (Trial Statistician), Arnaud Roth, Rob
McWilliams. InPACT/IRCI 004; Steve Nicholson (Chief Investigator),
Lucinda Billingham & Emma Hall (Trial Statisticians), Curtis
Pettaway. rEECur; Martin McCabe (Chief Investigator), Keith
Wheatley (Trial Statistician), Jeremy Whelan.Age-standardised incidence rates in 2011 for new
cases of SCCA were 1.5 (UK) and 1.7 (USA) per
100,000, comprising 0.4% of new cancers [2,3]. Local
relapse occurs in 20% patients treated with chemora-
diotherapy; metastases in 10–17%. According to the
Surveillance, Epidemiology and End Results (SEER)
Program, estimated 5-year survival is 32% with meta-
static disease [2].
The main aims of InterAACT are to: provide pro-
spective randomised evidence for first-line treatment of
inoperable locally advanced or metastatic SCCA; estab-
lish the optimal chemotherapy backbone for combina-
tion with new targeted agents for future trials; allow
further exploration of tumour biology; promote the
future development of selective therapeutic strategies;
and establish set-up and recruitment feasibility of inter-
national SCCA trials. The longer-term intention is a
phase III RCT of adding novel agents to the chosen reg-
imen from InterAACT.
Recruitment rate was the main concern during design
stage; anticipated enrolment is only 30 pts/year, despite
international collaboration. The primary outcome mea-
sure is response rate, estimated as 40% with cis-
platin + 5-FU. A clinically relevant improvement by
10–50% with carboplatin + paclitaxel required 388
patients/arm using a standard sample size calculation
with 2-sided 5% significance level and 80% power; and
an infeasible 25 years’ accrual. Researchers instead
chose a Simon, Wittes and Ellenberg randomised selec-
tion trial design [4], requiring 40 patients/arm, for the
same target difference and power. Completing accrual
should take approximately 3 years. There is, however,
limited protection of the Type 1 error in this design.
If the trials regimens have very similar response rates,
the procedure will pick one by chance. The regimen with
fewest severe toxicities will be accepted if the observed
response rate is the same. Better quality-of-life (EORTC
QLQ-C30, EQ-5D-5L) will decide if toxicity is also
equal. If no winner is apparent after assessing activity,
toxicity and QoL, a strong recommendation for which
regimen to use in future phase III trials of combination
therapy cannot be made.
2.2. Accept a greater type I error (salivary gland cancer)
The type I error is the probability of wrongly reject-
ing a null hypothesis (H0); erroneously concluding the
research treatment is efficacious, active or interesting.
This is traditionally 5% i.e. 1/20. The type II error is
the probability of erroneously accepting the null
hypothesis; missing an interesting treatment. A higher
risk of type 2 errors is usually accepted, often 1/10 or
1/5, translating to 90% or 80% power, respectively.
One might decrease the required sample size by
accepting a type I error more like a typical type II error.
This approach is used in EORTC-1206-HNCG of
salivary gland carcinomas (SGC), a heterogeneous
Table 1
Trial names and registration.
Short name Full name Registration number
BALLAD/IRCI 002 A study to evaluate the potential benefit of adjuvant chemotherapy for small
bowel adenocarcinoma (SBA)
Pending application
Androgen deprivation therapy in
advanced SGCs/IRCI 007
A randomised phase II study to evaluate the efficacy and safety of
chemotherapy (CT) versus androgen deprivation therapy (ADT) in patients
with recurrent and/or metastatic, androgen receptor (AR) expressing,
salivary gland cancer (SGCs)
NCT01969578
HGUS/IRCI 006 A randomised double-blind phase II study evaluating the role of
maintenance therapy with cabozantinib in High Grade Undifferentiated
Uterine Sarcoma (HGUS) after stabilization or response to doxorubicin +/-
ifosfamide following surgery or in metastatic first line treatment
EudraCT 2013-000762-11;
NCT01979393
InterAACT/IRCI 003 An International multicentre open label randomised phase II Advanced Anal
Cancer Trial comparing cisplatin plus 5-fluorouracil versus carboplatin plus
weekly paclitaxel in patients with inoperable locally recurrent or metastatic
disease
NCT02051868
rEECur Trial of chemotherapy for relapsed and refractory Ewing sarcoma ISRCTN36453794
GOG-0277/IRCI 001 A phase III randomised trial of gemcitabine plus docetaxel followed by
doxorubicin versus observation for uterus-limited, high-grade uterine
leiomyosarcoma
EudraCT 2012-002852-17;
NCT01533207
MEKi ± AKTi in UM/IRCI 005 A randomised two-arm Phase II study of Trametinib alone and in
combination with GSK2141795 in patients with advanced uveal melanoma
EudraCT number – 2013-
002925-50; NCT01979523
InPACT/IRCI 004 International Penile Advanced Cancer Trial NCT02305654
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of head and neck cancers. Patients treated with chemo-
therapy (CT) have low response rates and poor out-
comes. There is compelling evidence from case
series for sensitivity to androgen deprivation therapy
(ADT) in androgen receptor-(AR)-expressing SGCs
[5–8]. Therefore, this trial compares ADT to CT in
treatment-naive recurrent and/or metastatic SGC,
restricted to salivary duct cancer and adenocarcinoma,
two histologies where AR-expression is more common.
The primary outcome measure is progression-free
survival (PFS). Patients must be treatment-naı¨ve to eval-
uate PFS in the main study, but an exploratory substudy
evaluates ADT in previously-treated patients.
The challenge was designing a trial with an accept-
able compromise between (i) level of scientific evidence
and (ii) feasibility in terms of trial size and duration.
Obtaining robust estimates of PFS for CT-treated
patients was difficult: published studies were small and
heterogeneous for histology, AR-expression and chemo-
therapy. The absence of good reference data strengthens
the case for randomisation. Single arm and non-com-
parative randomised designs were dismissed before
selecting a comparative randomised design. Discussion
focused on the consequences of relaxing type I and II
errors. As method of evaluating PFS, a time-to-event
(PFS curve comparison) approach was selected over a
binary (progression free rate at one time point relative
to accrual) to avoid arbitrary time point selection. This
choice contributed to reduction of sample size.
Pragmatic values for type I and II errors were
selected: 80% power and 10% one-sided significance.The target effect size of hazard ratio (HR) 0.56 was cho-
sen subsequently, based on 16 patients treated with
ADT; it is equivalent to increasing 6-months PFS from
60% to 75%. The design requires 76 randomised patients
over 2 years which was thought achievable after survey-
ing interested institutions. Fifty-five PFS events are
expected 1 year after accrual completes. The primary
analysis is frequentist. A sensitivity analysis based on
Bayesian methodology will assess the robustness of the
conclusions for various prior distributions of the treat-
ment effect hazard ratio.
2.3. Abandon a trial early for lack-of-benefit (uterine
leiomyosarcoma)
There is an opportunity cost in continuing to assess a
treatment that is unlikely to change practice, a cost felt
more keenly in rare cancers. One may therefore consider
interim futility analyses, which make assumptions about
future data. This approach is used in uterine leiomyosar-
coma (uLMS), a tumour of uterinemuscle, prone tometas-
tasising. Incidence is estimated at 0.4–0.64/100,000
women/year [9,10]; 60% present with early stage disease.
Uterine-confined, high-grade uLMS has a post-operative
recurrence rate of 50–70% at 2–3 years [11,12]. Observa-
tion after complete resection of uterus-limited disease is
considered standard. Chemotherapy regimens reported
to achieve good objective responses in metastatic disease
include doxorubicin, doxorubicin and ifosfamide, gemcit-
abine, and fixed-dose rate gemcitabine and docetaxel.
Most published uLMS studies have been non-ran-
domised. No adjuvant therapy has demonstrated
Table 2
Trial descriptions.
Short name  Population Incidence (per
100,000/year)
Concise description of the research
question(s)
Sample size
(patients)
Notes on trial design (Purpose, Primary end-point,
Design type)
BALLAD/ IRCI 002  Small bowel adenocarcinoma
 Stage I-III
 Fully resected
 Fit for adjuvant fluoropyrimidine-based
chemotherapy
2.2–5.7
(Western
countries)
Q1-Adjuvant treatment versus conservative
management where uncertainty of
chemotherapy
Q2-Fluoropyrimidine ‘monotherapy’ versus
fluoropyrimidine + Oxaliplatin where
chemotherapy will be given
Q1: 300 –
455
Q2: 280–
425
Efficacy
Disease Free Survival
Uses a 20% 1-sided alpha and 80–90% power
Hazard ratio refined using an external expert opinion
prior (Bayesian)
Androgen deprivation therapy
in advanced SGCs/ IRCI 007
 Salivary gland cancer
 Histologically proven salivary duct cancer or
adenocarcinoma NOS
(not otherwise specified)
 Recurrent and/or metastatic
 Treatment naı¨ve
 Androgen receptor (AR) expressionP 70%
nuclei of neoplastic cells
2.5–3.0
(Western
countries)
Androgen deprivation therapy (ADT)
versus chemotherapy (CT)
76 Efficacy
Progression Free Survival
Korn design: inflated alpha at 10% 1-sided
Target increase PFS rate at 6 months from 60% to 75%
HGUS/IRCI 006  High-grade uterine sarcoma
 Locally advanced (stage III-IV) or residual
disease after primary surgery) or metastatic
 Non-progressive at end of standard
chemotherapy
0.07 Maintenance cabozantinib versus not 78 Activity
Progression Free Survival
Randomised blinded comparative phase II trial (Korn
design, inflated alpha at 15% 1-sided)
Target increase PFS at 4 months from 50% to 80%
InterAACT/IRCI 003  Inoperable locally recurrent or
 Metastatic squamous cell carcinoma of the
anus (SCCA)
 First line treatment
1.5–1.7
(CRUK and
SEER data)
Cisplatin plus 5-FU versus carboplatin plus
weekly paclitaxel
80 Set standard care; feasibility for future
Response Rate
Simon, Wittes & Ellenberg randomised selection trial
design
rEECur  Ewing sarcoma
 Relapsed/refractory
0.09 3 chemotherapy doublets and 1 arm single
agent (high dose)
500 Efficacy
Interim: Response Rate; Final: Event Free Survival
Multi-arm and multi-stage with arms dropping out by
forced decisions
Probability-based interpretation
GOG-0277/IRCI 001  Uterine Leiomyosarcoma
 Uterus-limited, High-grade
0.4–0.64 Adjuvant gemcitabine plus docetaxel
followed by doxorubicin versus observation
216 Efficacy
Overall Survival
80% power to detect HR = 0.625 at 5%
1-sided significance
MEKi +/- AKTi in UM/IRCI
005
 Uveal melanoma
 Metastatic
 No previous therapy for metastatic disease
0.43 Two experimental targeted therapies
evaluated: either trametinib 208 plus
GSK2141795 (MEK and AKT inhibition)
or trametinib alone (MEK inhibition)
80 Activity
Interim: Response Rate; Final: Progression Free
Survival
Randomization between 2 experimental arms 80%
power to detect HR = 0.56 at 5% 1-sided significance
InPACT/ IRCI 004  Squamous carcinoma of the penis who
have inguinal lymph node metastases
(i.e. locally-advanced disease)
 No previous chemotherapy or
chemoradiotherapy
1.5 (UK)
1570 cases in
2013 in US
1. role of neoadjuvant therapy and should it
be chemotherapy or chemoradiotherapy
2. role of prophylactic pelvic lymph node
dissection (PLND) following ILND in
patients at high risk of recurrence?
400 Efficacy
Overall Survival
Bayesian design incorporating two sequential
randomisations
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bine + docetaxel doublet followed by doxorubicin [11]
reported 78% 2-year PFS and 57% 3-year PFS. This
regimen was chosen for phase III comparison to obser-
vation until recurrence for women with high grade,
uterus-limited, completely resected, LMS.
Assessing treatment arms from quite different modal-
ities increases the challenge to recruitment. International
participation was sought to maximise accrual. Recur-
rence-free survival (RFS) was initially chosen as the
primary outcome measure, but there were concerns
about potential bias in assessments in the absence of
blinding, and blinding would not be feasible in a study
where the control arm is observation. Therefore,
survival was chosen as the primary outcome measure.
A high probability of early stopping for lack-of-benefit
is particularly desirable given the disease rarity and con-
trast between trial arms. More outcome events (and thus
statistical power) are available for RFS than survival at
any time. Therefore, the probability of early termination
under H0 is increased by replacing survival with RFS as
the interim outcome measure for lack-of-benefit, with
little or no power loss. This assumes that lack-of-benefit
in RFS will translate to lack-of-benefit in survival, a
reasonable assumption.
The interim futility boundary was set as HRP0.90 in
RFS to provide P65% probability of early termination
under H0. The loss in power for using RFS for the
interim analysis depends on the correlation between
the interim RFS and final survival test statistics. This
correlation is not known in advance, but, with reason-
able assumptions, the loss in power is estimated to be
between 0.75% and 1.9%. This loss can be off-set by a
small increase in observed number of deaths for the final
analysis.
2.4. Test only research treatments with early
discontinuation for lack-of-activity in absence of standard
(metastatic uveal melanoma)
Despite aggressive local management of primary
uveal melanoma (UM) with radiotherapy or surgical
enucleation, metastases develop within 15 years in 50%
patients [13–15]. Treatment has been improved for
advanced cutaneous melanoma [16–18], a common con-
dition, but no effective therapy has been approved for
patients with the far rarer metastatic UM. This is
highly-resistant to systemic therapy and prognosis is
poor, with median PFS 2–4 months.
Multiple molecularly-targeted treatment strategies
have been identified for clinical evaluation. Efficiently-
designed clinical trial and multicenter collaborative
efforts are required to test them.
No standard-of-care with demonstrable clinical activ-
ity is recognised against which experimental treatments
can be compared. A control arm of no-treatment,
perhaps placebo-blinded, may be justifiable but poseschallenges for patient and physician acceptance; control
with local standard management poses implementation
challenges. Dacarbazine (DTIC) and temozolomide
were considered internationally feasible control regi-
mens, but a single-arm study of temozolomide [19] and
RCT including DTIC and temozolomide demonstrated
insufficient activity [20,21].
Therefore, researchers agreed to assess two experi-
mental arms: trametinib-alone or trametinib + AKT
inhibitor. This two-arm randomised phase II study in
80 patients has a comparative final analysis and non-
comparative interim analyses.
The primary outcome measure is PFS, defined as time
from randomisation to the earliest of objective disease
progression (Response Evaluation Criteria in Solid
Tumours (RECIST)) or death from any cause. Median
PFS trametinib is estimated as 16 wk. With 80 patients
and 76 progression events, the probability is 80% of
detecting a treatment difference at a one-sided 5% signif-
icance level if the true HR = 0.56. This assumes accrual
of 24 months at 4 pt/m internationally, follow-up of
12 months. Patients will be assessed 8-weekly.
An early stopping rule for activity focuses on objec-
tive response rate (ORR; complete or partial response
using RECIST) after recruiting 40 patients. Accrual will
be terminated to either arm if <2 patients achieve ORR.
The 95% confidence interval’s upper bound for 1/20
ORR is 25%. Any arm passing the interim analysis con-
tinues accrual to the pre-planned total of 40 patients. If
there is just one such arm, it will be analysed as a single-
arm phase II study and the PFS distribution assessed.
The interim evaluation is justified by the rarity of disease
and potential for inactive treatments.
2.5. Balance scientific value and feasibility (high-grade
undifferentiated uterine sarcoma)
Opportunities to evaluate maintenance therapy are
unusual for rare cancers, but this is addressed in high-
grade undifferentiated uterine sarcoma (HGUS). Here,
a randomised double-blind approach is used to evaluate
maintenance therapy with cabozantinib after disease sta-
bilisation or objective response to doxorubicin-based
chemotherapy (CT).
Uterine sarcomas account for 1% female genital
tract malignancies and 3–7% uterine cancers [22].
HGUS, constituting 6% of uterine sarcomas, has limited
evidence concerning management; therapeutic strategies
typically follow practice for other soft tissue sarcomas
(STS) [23].
Prognosis of advanced HGUS is poor: median PFS
<4 months, median survival <12 months. New regimens
are needed. Disease stabilisation of STS can be achieved
with pazopanib so anti-angiogenic agents represent an
option. Maintenance therapy with anti-angiogenic
agents, e.g. cabozantinib, may prolong the chemother-
apy-induced response.
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cacy of standard chemotherapy. The original concept
was to enrol HGUS patients in the first-line setting, then
randomise chemotherapy-responders to maintenance
therapy with either study drug or placebo. A randomisa-
tion was envisaged for patients who recurred after first-
line chemotherapy. This grand study design would
address three objectives: the objective response to first-
line chemotherapy; the effectiveness of maintenance
treatment with an experimental anti-angiogenic agent;
and, response and survival in patients treated with the
experimental agent at time of disease progression. Such
a study would reduce time and costs compared to three
separate studies. Pharmaceutical industry support was
obtained only for the maintenance therapy question,
notably cabozantinib.
Recruitment to the maintenance study would be facil-
itated by permitting any first-line chemotherapy prior to
study enrolment but investigators wanted some hetero-
geneity in first-line chemotherapy. Therefore, eligible
patients must have received doxorubicin-based first-line
chemotherapy. National groups will use standard regi-
mens (limited to doxorubicin ± ifosfamide); a retrospec-
tive propensity-based [24] non-randomised evaluation of
the additional ifosfamide is planned.
The resulting trial includes only one randomisation:
cabozantinib versus placebo as maintenance therapy.
An improvement in PFS is of clinical benefit in such a
poor prognosis setting with limited treatments for recur-
rence; a 30% improvement in 4-months PFS from 50%
to 80% is targeted. Survival and toxicity are key second-
ary outcome measures. 76 patients will be recruited, to
randomise 54 patients, for 85% power to detect with a
one-sided 15% significance level.
Cross-over to cabozantinib at progression is permitted
which may appeal to participants, but complicates inter-
pretation of survival data. The trial will also yield valu-
able translational research to inform further research.
2.6. Incorporate Bayesian elements to quantify resulting
level of information (small bowel adenocarcinoma)
The previous designs each use a frequentist approach
to the primary analyses. Bayesian designs are increas-
ingly used, particularly in phase I studies [25] and adap-
tive designs [26], and may increase efficiency in these
contexts. The Bayesian approach also has attractive fea-
tures in rare cancers. It allows the incorporation of
external information, including subjective information,
into the estimation of treatment effects [27], supplement-
ing the restricted information from the study itself
[28,29]. The BALLAD study mixes frequentist and
Bayesian inferential frameworks.
BALLAD is a study in stage I–III small bowel adeno-
carcinoma (SBA), representing <5% gastrointestinal
cancers. There were 2000 new cases and 400 deathsfrom SBA in the USA in 2008 [30,31]. The annual
incidence is 0.22–0.57/100,000 inhabitants in Western
countries [32]. Prognosis can be favourable and in
stages I–III, 75% of diagnoses, are potentially curable
[30].
There are no RCTs of adjuvant treatment following
initial surgery in stage I–III SBA, but the proven bene-
fits of fluoropyrimidine-based adjuvant therapy, with
or without oxaliplatin, in colorectal cancer (CRC) sug-
gest this may be worthwhile. Therefore, BALLAD aims
to answer two questions in resected stage I–III SBA.
Where the clinician is uncertain, what is the value of
adjuvant post-operative chemotherapy over observa-
tion? Where the clinician is convinced of the value of
adjuvant treatment, what is the value of adding oxalipl-
atin to adjuvant post-operative fluoropyrimidine-based
chemotherapy?
The study design balances the need to produce per-
suasive evidence with the need for a sample size con-
strained by patient numbers and time. Four key design
choices reflect these constraints.
First, disease-free survival (DFS) was selected as the
primary outcome measure, rather than survival. This
reduces the sample size as DFS events occur earlier; evi-
dence from the colorectal cancer setting supports surro-
gacy of DFS for survival.
Second, a conventional (frequentist) design would
ideally have been selected, but the power and signifi-
cance levels for traditional design resulted in an infea-
sible target of 1500 patients. A hybrid approach was
therefore selected, using a standard randomised phase
II design, and using Bayesian techniques to incorpo-
rate subjective clinician estimates of treatment effect
based on external evidence. This hybrid approach
requires some objective statistically-significant evidence
of treatment benefit from the study data; the study is
designed to have 80–90% power to detect HR = 0.75
for each question at the 20% 1-sided significance level.
If the results are statistically significant at 20%, the
data will be combined with clinician estimates of the
treatment benefit, based on their interpretation of
external evidence from the relevant literature to pro-
vide an overall combined estimate. These clinician
estimates will be obtained in the first year of recruit-
ment [33].
Third, to facilitate recruitment, flexibility is allowed
in the choice of fluoropyrimidine. Patients allocated to
chemotherapy in the first randomisation may also be
randomised to receive oxaliplatin or not, boosting
recruitment to the second randomisation and the overall
efficiency of the design.
Finally, the study may be stopped early for futility
when half the events have been observed. Recruitment
will be in the range of 545–860 patients. The success of
recruitment to each randomisation will be assessed
independently.
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carcinoma of the penis [InPACT])
A key motivation for Bayesian designs is focusing on
estimation rather than hypothesis testing; trial data are
used to reduce uncertainty about the size of the treat-
ment effect and inform future clinical practice [29]. A
‘reverse philosophy’ means starting with the number of
patients and events that could be feasibly recruited
and accumulated within a timescale, then assessing
whether that amount of data would have sufficient value
to justify a trial. Such feasibility issues are more promi-
nent in rare diseases.
The design evaluates the clinical utility of the trial by
(i) demonstrating the information that a Bayesian anal-
ysis could provide for a range of possible observed trial
results and prior distributions; and (ii) assessing the
operating characteristics of the design i.e. the chance
of erroneous conclusions from typical decision criteria
under a range of underlying true scenarios using
simulation.
The InPACT trial uses this approach for patients with
inguinal lymph node metastases from squamous carci-
noma of the penis i.e. locally advanced disease. The
annual incidence in the UK is 1.5/100,000, with 558
new cases in 2011 and 106 deaths in 2012 [34]. There were
1570 new cases and 310 deaths in the USA in 2013 [35].
The trial has two independent randomisations,
addressing key questions in the clinical pathway: First,
the role of neoadjuvant therapy prior to standard sur-
gery, by randomising to chemotherapy, chemoradiother-
apy, or no neoadjuvant therapy. Second, the role of
prophylactic pelvic lymph node dissection (PLND) in
only higher-risk patients following their standard sur-
gery with therapeutic inguinal lymph node dissection
(ILND). The primary outcome measure is overall survival.
The trial will accrue for 5 years with 2 years follow-
up. This should yield at least 400 patients, with 176
patients contributing to the neoadjuvant therapy ques-
tion, including 132 to the sub-question of type of neoad-
juvant therapy, and 240 to the PLND question. The
predicted numbers of deaths for the analyses are 88/
176, 84/132 and 181/240, respectively. The posterior
probability distributions should provide sufficient cer-
tainty (86% on average across different questions and
different priors) that the treatment is effective to inform
clinical practice, if a modest treatment effect is observed
(i.e. HR = 0.8). There is a high probability (81% on
average) of selecting the right treatment, using Bayesian
decision rules, if a treatment has a true modest, clini-
cally-relevant effect (HR = 0.8); and a low probability
(8% on average) of accepting a treatment when there is
a true negative effect (HR = 1.25). There is a moderately
high chance (39% on average) of incorrectly accepting
the ‘experimental treatment’ for future use if there is
no true effect (HR = 1); this is considered an acceptable
trade-off.The design uses four off-the-shelf prior distributions
(non-informative, sceptic, extreme sceptic, enthusiast),
incorporating the equivalent of 20 deaths to represent
weak prior evidence or beliefs in the latter three cases.
The trialists intend to perform a systematic review of
the literature in order to create relevant evidence-based
priors for use in the final analysis.
2.8. Multiple concurrent treatments, interim analysis
based on merit
Most trials randomise patients between only two
arms, but, in some circumstances, there are more agents,
combinations or other approaches to treatment suitable
for testing. How should researchers select which to take
forward into their new two-arm trial? There are oppor-
tunity costs in pursuing just one treatment, particularly
if results are not positive, and these are felt even more
keenly in rare diseases.
An alternative to multiple parallel 2-arm trials is a
single multi-arm trial where a series of research arms
are assessed in parallel against a common control arm.
The control arm patients efficiently contribute to each
pairwise comparison and only one protocol is required.
This approach is extendable with intermediate stop-
ping rules, like those in the uterine leiomyosarcoma
study, which stop recruitment early to insufficiently
active research arms. One implementation is the multi-
arm multi-stage (MAMS) approach where recruitment
is stopped early to research treatments that are insuffi-
ciently active based on pre-specified lack-of-sufficient-
benefit analyses [36,37]. Recruitment continues based
only on merit in the observed data; recruitment would
completely stop early only if all research arms showed
a lack-of-sufficient-benefit; or would continue to the
control arm and any research arms that look sufficiently
interesting. Researchers would need to be prepared to
recruit to the maximum number of patients, although
this is unlikely given the unfortunate situation that most
new treatments work less well than hoped [38].
This approach is successfully implemented in com-
mon diseases [39,40] and potential trials have been
developed in rare cancers, notably osteosarcoma and
ocular melanoma, where investigators saw it as an
efficient approach. Access to the necessary drugs was
problematic for an ocular melanoma proposal, but the
European and American Osteosarcoma Study (EURA-
MOS) Strategy Group remains committed to a multi-
arm multi-stage international comparison in the future
when further early phase studies have been completed.
The multi-arm approach has been supported in rare
diseases outside of cancer e.g. erosive lichen planus of
the vulva, a very rare dermatological condition, where
a four-arm trial (three research arms) will commence
recruitment in the UK in 2014. Although there are no
examples of its implementation in rare cancers so far,
the design is a weapon in our armamentarium.
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sarcoma)
Assuming the efficiency of running multi-arm trials,
alternative ways of selecting which treatments should
continue to be assessed may be investigated. These could
incorporate randomised selection designs and probabil-
ity-based interpretation, using Bayesian posterior prob-
ability distributions with a non-informative prior. This
approach is used in Ewing sarcoma, a rare cancer
mainly in children and young adults. Initial treatment
leads to event-free survival (EFS) of 50% at 5 years
[41]. Prognosis in both refractory disease after induction
chemotherapy and after recurrence is very poor. Several
chemotherapy regimens are used at recurrence, but there
is no randomised evidence driving treatment decisions;
only limited data from small single-arm series, making
comparison of regimens very unreliable. The four
re-induction regimens most widely used are: topotecan +
cyclophosphamide (TC), irinotecan + temozolomide (IT),
gemcitabine + docetaxel (GD) and high-dose ifosfamide
alone (IFOS).
The rEECur trial adopts an adaptive multi-arm
design with forced selection at a series of pre-specified
interim analyses. The initial Phase II stage, with
response as the primary outcome measure, randomises
50 patients to each of four arms: TC, IT, GD and IFOS.
Recruitment to one arm will be stopped at that point
and to a second arm after a further 25 patients/arm.
The remaining two arms will continue to a Phase III
evaluation with EFS as the primary outcome measure.
The probabilities of ‘dropping’ the best arm at each
stage have been calculated under various scenarios.
For example: if the true response rate is 50% for the best
arm and 40% for the other arms, there are 3% and 5%
chances of erroneously dropping the best arm after 50
and 75 patients/arm, respectively; the cumulative
probability of 8%. Response is the primary intermediate
outcome measure but other factors (toxicity and conve-
nience) will be considered in decision-making. The
Independent Data Monitoring Committee (IDMC) will
make this decision.
The Phase III element adopts a probability-based
approach to interpretation. The sample size calculation
for a conventional design, with 2-sided alpha 5% and
80% power, requires 660 patients for an absolute differ-
ence of 10% in EFS. All are accepted regimens so there
is no clinical need to be 97.5% certain that one regimen
is better than the other. If there is, say, an 80% chance
that EFS is better with one regimen (equivalent to 2-
sided p = 0.4) with little difference in toxicity, the clinical
community would accept this as the standard-of-care for
future trials. The decision as to which regimen is the bet-
ter after the final analysis will also take account of all
relevant information.
The researchers see rEECur as the beginning of an
ongoing programmatic collaboration, with new regimensintroduced for assessment, as new arms or as factorial
comparisons.
3. Discussion
The IRCI trialists have contributed to a joint discus-
sion of the key parameters and main concerns in
designing and executing clinical trials in rare cancer pop-
ulations. Section 2 discussed some of the thinking
behind the diverse approaches that were selected. We
summarise the joint themes coming from the discussion.
The diseased population available for sampling limits
the application of the laws of probability as applied in
biostatistics but the laws do not change because of
rarity. One main role of statistics in the set-up and inter-
pretation of clinical trials is to delineate the uncertainty
around the results. The previous examples illustrate
many approaches to performing credible clinical trials.
What makes a credible trial in rare cancers?
Comparative data: The lack of robust historical data
greatly affects the starting point of trial design. Absence
of an evidence-based standard-of-care commonly leads
to heterogeneity in practice. Design assumptions often
use small series or extrapolation from other settings.
There may be little agreement on standard parameters
such as prognostic factors and expected outcomes.
Randomisation becomes a must-have in such situation,
allowing causation and the establishment of some levels
of evidence. Indeed, randomisation is usually required
for inclusion in the IRCI network.
Correct quantification of risks: A second element is
correct delineation of the resulting error margins.
Whether in a frequentist or Bayesian interpretation, tri-
alists need to agree upfront on acceptable false positive
(type 1 error) and false negative (type 2 error) rates. A
frequently used ploy in rare cancer trials is to soften
error rates, thus restricting samples sizes at the expense
of higher risks of false conclusions.
The result in the external world: The third and final
element for a credible trial is the hardest one, and is in
the eye of the beholder. Regulators, clinicians, patients,
pharmaceutical companies and payers all have their own
angle of interpretation, as in common diseases. The
differences in position between these stakeholders may
be particularly apparent with increased uncertainty.
An RCT ideally leads to the same interpretation by all
stakeholders, matching the intent of the trialists, but this
may be a utopian view. However, international collabo-
ration, and upfront agreement on the trial settings by a
large body of partners, upfront involvement of regula-
tors and patient organisations can only help.
To further specify, as for any trial, the objective is
essential. The conclusion sought may be definitive or
practice-changing, a phase III-type question, or it might
be feasibility, activity or treatment selection, a phase II-
type question. The former faces considerable hurdles in
the rare disease setting. For more common cancers, the
280 J. Bogaerts et al. / European Journal of Cancer 51 (2015) 271–281‘rules’ are – at least implicitly – fairly well agreed within
the community, and, ultimately, the regulator.
We advocate that if a trial is meant to be definitive or
practice-changing (i.e. no follow-on trial of the same
question is expected), it should be labelled as a Phase
III trial, despite pragmatic compromises on sample size,
error margins and other design elements. If all efforts –
including wide international collaboration—have been
made to enable the largest enrolment, the community
will need to interpret the results as potentially practice
defining. It is essential to seek broad consensus within
the expert community that the trial, if positive, would
change practice, and to seek concurrence of regulators
and other stakeholders. In some other situations, a
randomised Phase II trial can give the community the
necessary confidence to run the true next Phase III trial
as a follow-up.
In rare cancer trials, we want to warn against some
misconceptions. The first is a blanket appeal for ‘statis-
tical efficiency’, suggesting that more can be achieved
by trying harder. This is a misnomer, because any clin-
ical trial carried out without rigour and without a
proper design would be unethical. The call for efficiency
is a placeholder for issues that are of importance in any
clinical trial, but tend to be exacerbated by expectation
of low accrual and knowledge that few trials can be
undertaken in the population. There are multiple ways
to balance the scarcity of patients and the objective of
the trial. The variety of approaches at the IRCI work-
shop was striking, and we have illustrated these, above.
The choice of outcome measures will critically affect
trial design. Intermediate or potentially surrogate end-
points allow smaller trials but an inappropriately early
outcome measure must not be selected just to reduce
the trial’s size. Multiple or staged outcome measures
may be considered. Matters of multiple testing should
be explicitly discussed. Recruitment may be stopped
early to arms that are underperforming; the opportunity
costs in chasing false hopes are amplified in rare cancers.
Early stopping rules, using lack-of-activity or futility-
based measures, might be better accepted by trial teams
in the context of multi-arm trials where the hard-won
research activity is majorly altered rather than stopped
completely.
Care must be taken in relaxing the type I and type II
errors, especially if the intent is to change practice. It
seems rational to allow a higher type I error where few
options are open in the foreseeable future and a higher
type II error if many candidate treatments exist. Again,
this risk is to be embraced by the relevant clinical com-
munity and the regulators to ensure that efforts are
worthwhile.
A second, more opaque danger in rare cancer trials is
to try to ask too many questions in a single trial. In the
absence of good prior scientific data, it is a dangerous
choice to try for too much. In common cancers, mostdefinitive studies follow a traditional design with respect
to patient population, course of disease and line of
therapy. Many questions are typically open for any rare
disease. The prospect of a trial in a rare disease can make
researchers try to tackle all relevant questions simulta-
neously. This may lead to loss in focus, inability to define
the primary question, delayed development and funding
problems. The trials discussed above are all more or less
open to such criticism, reflecting the need for clinical tri-
als and the risk of overburdening the design.
We cannot discuss here the practical challenges in
conducting clinical trials across multiple countries but
note that international collaboration is a considerable
challenge, even when there is desire from the research-
ers. Navigating the regulatory requirements from vari-
ous authorities can be daunting but necessary for
success. We also cannot discuss translational research,
but all trials must collect and process samples in a coor-
dinated way in order to understand the diseases and
investigate biological data with consistently collected
prospective data.
4. Conclusion
The challenges and risks in designing and conducting
a trial to provide sufficient evidence remain enormous in
rare diseases, despite the constraints of sample size and
insufficient background information. Trial designs can
be undertaken using a wide array of possibilities, as
illustrated. There is no ‘one size fits all’ solution. We
have set out some examples of approaches accepted by
IRCI so far so that future researchers might consider
the relative positives and negatives.
In order to make progress in the treatment of rare dis-
eases, decisions to change practice will have to be based
on less direct evidence from clinical trials than in more
common diseases. Approaches to aid decision making by
augmenting direct randomised trial evidence in a struc-
tured manner with external sources should be explored.
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